Back to search

Article

Safety and Immunogenicity of an Inactivated Whole Virion SARS-CoV-2 Vaccine, TURKOVAC, in Healthy Adults: Interim Results from Randomised, Double-Blind, Placebo-Controlled Phase 1 and 2 Trials

2022-04-22

Abstract excerpt

Background: Safe and effective vaccine options is crucial to fight against COVID-19 pandemic. We report interim safety and immunogenicity findings of the phase 1&2 trials of ERUCoV-VAC, an inactivated whole virion SARS-CoV-2 vaccine. <br><br>Methods: Double-blind, randomised, single centre, phase 1&2 trials included SARS-CoV-2 seronegative healthy adults aged 18-55 years (18-64 in phase 2). Participants, were assi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
73c123bd-5a98-5107-a2f2-62fc2ff25361
DOI
10.2139/ssrn.4090492
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety and Immunogenicity of an Inactivated Whole Virion SARS-CoV-2 Vaccine, TURKOVAC, in Healthy Adults: Interim Results from Randomised, Double-Blind, Placebo-Controlled Phase 1 and 2 TrialsDOI 10.2139/ssrn.4090492
A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and diseaseSemantic proximity
An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccineSemantic proximity
Safety and Immunogenicity of SII-NVX-CoV2373 (COVID-19 Vaccine) In Adults in a Phase 2/3, Observer-Blind, Randomised, Controlled StudySemantic proximity
Efficacy and Safety of an Inactivated Whole-Virion SARS-CoV-2 Vaccine (CoronaVac) in Brazilian Healthcare Professionals: The PROFISCOV TrialSemantic proximity
A phase 3, randomised, double-blind, placebo-controlled clinical trial for adult evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine (ABDALA-3 Study)Semantic proximity
Efficacy and Safety of an Inactivated Whole-Virion Vaccine Against COVID-19, QazCovid-in®, In Healthy Adults: A Multicentre, Randomised, Single-Blind, Placebo-Controlled Phase 3 Clinical Trial With a 6-Month Follow-UpSemantic proximity
The efficacy, safety and immunogenicity Nanocovax: results of a randomized, double-blind, placebo-controlled Phase 3 trialSemantic proximity
A Phase 3, Randomised, Double-Blind, Placebo-Controlled Clinical Trial for Adult Evaluation of the Efficacy and Safety of a Sars-Cov-2 Recombinant Spike Rbd Protein Vaccine (Abdala-3 Study)Semantic proximity
Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trialSemantic proximity
Safety and efficacy of two immunization schedules with an inactivated SARS-CoV-2 vaccine in adults. A randomized non-inferiority clinical trialSemantic proximity
Safety and Immunogenicity of CpG 1018 and Aluminium Hydroxide-Adjuvanted SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901: A Large-Scale Double-Blind, Randomised, Placebo-Controlled Phase 2 TrialSemantic proximity
Real-world effectiveness and non-inferiority evaluation and comparison of mRNA- and protein-based COVID-19 vaccines: a randomized study protocol (BEEHIVE)Semantic proximity
Select a neighboring publication to make it the new centre.